The detrimental impact of the downregulation of the glucagon-like peptide-1 (GLP-1) pathway in ALS is well established, exacerbating disease progression through various mechanisms, including impaired neuroprotection, metabolic dysregulation, mitochondrial dysfunction, excitotoxicity, and neuroinflammation [31]. This evidence concerns the gene GCG and amyotrophic lateral sclerosis.